China Meheco(SH:600056) 智通财经网·2025-09-23 08:18Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical has received approval from the National Medical Products Administration for the supplement application of Lincomycin Hydrochloride Injection, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Product Approval - Tianfang Pharmaceutical's Lincomycin Hydrochloride Injection is now approved for use, which is primarily indicated for severe infections caused by sensitive strains such as Streptococcus, Pneumococcus, and Staphylococcus [1] - The approval includes a supplement application notification, enhancing the product's regulatory standing [1] Group 2: Market Impact - The drug's passage through the consistency evaluation will provide greater support in areas such as medical insurance payments and procurement by medical institutions, according to national policies [1] - This approval is expected to enhance the market competitiveness of Lincomycin Hydrochloride Injection and further expand its market share [1]